{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:04:24Z","timestamp":1786637064425,"version":"build-2736575974"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Guangxi Zhuang Autonomous Region Health Department Self-Funded Project","award":["Z-A20220148"],"award-info":[{"award-number":["Z-A20220148"]}]},{"name":"Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project","award":["s2022006"],"award-info":[{"award-number":["s2022006"]}]},{"name":"Guangxi Traditional Chinese Medicine Appropriate Technology development and Promotion Project","award":["GZSY22-55"],"award-info":[{"award-number":["GZSY22-55"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:p>\n                    This retrospective cohort study evaluates the clinical effects of an antagonist protocol on in vitro fertilization and intracytoplasmic sperm injection among infertile women with polycystic ovary syndrome. A propensity score matching analysis was conducted of 402 infertile women diagnosed with polycystic ovary syndrome undergoing in vitro fertilization\/intracytoplasmic sperm injection cycles. The patients were divided into 2 groups: GnRH antagonist (GnRH-ant) pretreatment protocol (n\u2005=\u2005202) and non-pretreatment protocol (n\u2005=\u2005200). The primary outcome was the high-quality embryo rate. The metaphase II (MII) oocyte rate was calculated. After adjusting for confounders, the high-quality embryo rate (48.29% vs 42.74%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.010) was found to be significantly higher in the pretreatment group. However, the number of retrieved oocytes (12.00 vs 12.00,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.878), the MII oocyte rate (76.6% vs 76.0%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.663), the incidence of ovarian hyperstimulation syndrome (6.82% vs 2.27%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05), and the cycle cancelation rate (51.52% vs 51.52%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05) were not significantly different between the 2 groups. Similar results were obtained in the propensity score matching analysis of live birth rate (LBR, 46.88% vs 40.63%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.476). GnRH-ant pretreatment protocol resulted in increased high-quality embryo rates without increasing the cycle cancelation rate and the incidence of ovarian hyperstimulation syndrome. The number of retrieved oocytes, the MII oocyte rate, and the clinical pregnancy outcomes did not differ after GnRH-ant pretreatment.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000042965","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:01:05Z","timestamp":1751295665000},"page":"e42965","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effect of GnRH antagonist pretreatment before controlled ovarian stimulation in antagonist protocol for infertile women with PCOS undergoing IVF\/ICSI: A propensity score matching analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-0411","authenticated-orcid":false,"given":"Huanying","family":"Liang","sequence":"first","affiliation":[{"name":"Graduate School of Guangxi Medical University, Nanning, Guangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Genetics Center, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Genetics Center, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangchuan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Genetics Center, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate School of Guangxi Medical University, Nanning, Guangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Genetics Center, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-2599","authenticated-orcid":false,"given":"Liling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Genetics Center, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260813","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0140-6736(84)92840-X","article-title":"Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins.","volume":"2","author":"Porter","year":"1984","journal-title":"Lancet"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"265","DOI":"10.17772\/gp\/62205","article-title":"Flexible GnRH antagonist protocol vs. long GnRH agonist protocol in patients with polycystic ovary syndrome treated for IVF: comparison of clinical outcome and embryo quality.","volume":"87","author":"Trenki\u0107","year":"2016","journal-title":"Ginekol Pol"},{"key":"R3-20260813","first-page":"257","article-title":"2023 update on PCOS management: from diagnosis to long-term outcomes.","volume":"29","author":"Zhang","year":"2023","journal-title":"Hum Reprod Update"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"hoaa067","DOI":"10.1093\/hropen\/hoaa067","article-title":"Erratum: ESHRE guideline: ovarian stimulation for IVF\/ICSI.","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"key":"R5-20260813","first-page":"hoae025","article-title":"ESHRE guideline: ovarian stimulation in PCOS (2024 revision).","volume":"2024","year":"2024","journal-title":"Hum Reprod Open"},{"key":"R6-20260813","first-page":"109","article-title":"Expert consensus on the standardized application of antagonist protocols in assisted reproduction (Chinese).","volume":"42","year":"2022","journal-title":"Chin J Reprod Contraception"},{"key":"R7-20260813","first-page":"297","article-title":"Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol.","volume":"10","author":"Eftekhar","year":"2012","journal-title":"Iran J Reprod Med"},{"key":"R8-20260813","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2147\/DDDT.S201871","article-title":"Comparative proteomics reveal negative effects of gonadotropin-releasing hormone agonist and antagonist on human endometrium.","volume":"13","author":"Chen","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R9-20260813","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/clinem\/dgz100","article-title":"Scaffold-free endometrial organoids respond to excess androgens associated with polycystic ovarian syndrome.","volume":"105","author":"Wiwatpanit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20260813","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s43032-020-00194-7","article-title":"Hyperandrogenic milieu dysregulates the expression of insulin signaling factors and glucose transporters in the endometrium of patients with polycystic ovary syndrome.","volume":"27","author":"Lee","year":"2020","journal-title":"Reprod Sci"},{"key":"R11-20260813","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1186\/s12913-018-3585-9","article-title":"Assessment of the development of assisted reproductive technology in Liaoning Province of China, from 2012 to 2016.","volume":"18","author":"Fang","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"R12-20260813","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00404-019-05210-z","article-title":"Effect of pretreatment with combined oral contraceptives on outcomes of assisted reproductive technology for women with polycystic ovary syndrome: a meta-analysis.","volume":"300","author":"Song","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"R13-20260813","first-page":"CD006109","article-title":"Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive technique.","volume":"5","author":"Farquhar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20260813","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/humrep\/dew325","article-title":"Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.","volume":"32","author":"Wei","year":"2017","journal-title":"Hum Reprod"},{"key":"R15-20260813","first-page":"1672","article-title":"Effect of E2 changes on pregnancy dyspepsia in IVF-ET after addition of antagonist (Chinese).","volume":"40","author":"Li","year":"2020","journal-title":"J South Med Univ"},{"key":"R16-20260813","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.fertnstert.2011.01.028","article-title":"Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization\/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study.","volume":"95","author":"Blockeel","year":"2011","journal-title":"Fertil Steril"},{"key":"R18-20260813","first-page":"1237","article-title":"Comparison of clinical efficacy of two preconditioning protocols in the treatment of polycystic ovary syndrome (Chinese).","volume":"48","author":"Juanjuan","year":"2020","journal-title":"Chin J Clini"},{"key":"R19-20260813","first-page":"337","article-title":"Effects of human menopausal gonadotropin on zona pellucida and pregnancy outcomes of ovarian stimulation protocols.","volume":"13","author":"He","year":"2015","journal-title":"Iran J Reprod Med"},{"key":"R20-20260813","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","article-title":"The international glossary on infertility and fertility care, 2017.","volume":"108","author":"Zegers-Hochschild","year":"2017","journal-title":"Fertil Steril"},{"key":"R21-20260813","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/humupd\/dmq032","article-title":"Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.","volume":"17","author":"Qiao","year":"2011","journal-title":"Hum Reprod Update"},{"key":"R22-20260813","first-page":"357","article-title":"Analysis of influencing factors of embryo quality and pregnancy outcome during thawing transplantation in PCOS patients.","volume":"42","author":"Zexin","year":"2022","journal-title":"Chin J Reprod Contraception"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12958-024-01337-0","article-title":"Oxidative stress and energy metabolism abnormalities in polycystic ovary syndrome: from mechanisms to therapeutic strategies.","volume":"22","author":"Yan","year":"2024","journal-title":"Reprod Biol Endocrinol"},{"key":"R24-20260813","doi-asserted-by":"crossref","first-page":"e18635","DOI":"10.7717\/peerj.18635","article-title":"Effect of basal luteinizing hormone\/follicle-stimulating hormone ratio on clinical outcome of in vitro fertilization in patients with polycystic ovarian syndrome: a retrospective cohort study.","volume":"12","author":"Shan","year":"2024","journal-title":"PeerJ"},{"key":"R25-20260813","doi-asserted-by":"crossref","first-page":"e13024","DOI":"10.1016\/j.heliyon.2023.e13024","article-title":"Elevated baseline LH\/FSH ratio is associated with poor ovulatory response but better clinical pregnancy and live birth in Chinese women with PCOS after ovulation induction.","volume":"9","author":"Xia","year":"2023","journal-title":"Heliyon"},{"key":"R26-20260813","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.3390\/ijms26094121","article-title":"Autoantibodies targeting the hypothalamic-pituitary-ovarian axis in polycystic ovary syndrome: emerging key players in pathogenesis?","volume":"26","author":"Akpang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R27-20260813","doi-asserted-by":"crossref","first-page":"106773","DOI":"10.1016\/j.jsbmb.2025.106773","article-title":"FSH, LH, lipid and adipokines in polycystic ovary syndrome: clinical biochemistry insights for diagnosis and management.","volume":"251","author":"Merza","year":"2025","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R28-20260813","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mce.2012.07.011","article-title":"Disordered follicle development.","volume":"373","author":"Chang","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"R29-20260813","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/humupd\/dmi036","article-title":"A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome.","volume":"12","author":"Heijnen","year":"2006","journal-title":"Hum Reprod Update"},{"key":"R31-20260813","first-page":"189","article-title":"GnRH antagonist pretreatment alters LH receptor isoform expression in human granulosa cells.","volume":"31","author":"Gonz\u00e1lez-Navarrete","year":"2025","journal-title":"Hum Reprod Update"},{"key":"R33-20260813","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5653\/cerm.2018.45.3.135","article-title":"Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: a preliminary randomized trial.","volume":"45","author":"Shin","year":"2018","journal-title":"Clin Exp Reprod Med"},{"key":"R34-20260813","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/0300060517704140","article-title":"Predicting the outcome of different protocols of in vitro fertilization with anti-Mu\u00fcllerian hormone levels in patients with polycystic ovary syndrome.","volume":"45","author":"Chen","year":"2017","journal-title":"J Int Med Res"},{"key":"R35-20260813","first-page":"6","article-title":"Effect of premature LH elevation on IVF-ET outcome of GnRH antagonist cycle in patients with polycystic ovary syndrome.","volume":"31","author":"Shan","year":"2022","journal-title":"J Reprod Med"},{"key":"R36-20260813","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.fertnstert.2013.05.031","article-title":"Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6.","volume":"100","author":"Hamdine","year":"2013","journal-title":"Fertil Steril"},{"key":"R37-20260813","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0015-0282(02)04696-4","article-title":"Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome.","volume":"79","author":"Elkind-Hirsch","year":"2003","journal-title":"Fertil Steril"},{"key":"R38-20260813","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.anireprosci.2011.07.020","article-title":"Administration of a gonadotropin-releasing hormone antagonist to mares at different times during the luteal phase of the estrous cycle.","volume":"127","author":"Evans","year":"2011","journal-title":"Anim Reprod Sci"},{"key":"R39-20260813","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1071\/RD09275","article-title":"Positive effect of FSH but not LH on early development of the dominant follicle in mares.","volume":"22","author":"Checura","year":"2010","journal-title":"Reprod Fertil Dev"},{"key":"R40-20260813","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mrd.21175","article-title":"Regulation of the G2\/M transition in rodent oocytes.","volume":"77","author":"Downs","year":"2010","journal-title":"Mol Reprod Dev"},{"key":"R41-20260813","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s43032-019-00137-x","article-title":"Luteinizing hormone action in human oocyte maturation and quality: signaling pathways, regulation, and clinical impact.","volume":"27","author":"Arroyo","year":"2020","journal-title":"Reprod Sci"},{"key":"R42-20260813","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00001703-200206000-00004","article-title":"Is luteinizing hormone needed for optimal ovulation induction?","volume":"14","author":"Balasch","year":"2002","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R43-20260813","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1185\/03007990802374815","article-title":"Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect.","volume":"24","author":"O\u2019Dea","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R44-20260813","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rbmo.2011.03.023","article-title":"Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective.","volume":"23","author":"Wong","year":"2011","journal-title":"Reprod Biomed Online"},{"key":"R45-20260813","first-page":"456","article-title":"LH threshold dynamics in PCOS: A multicenter randomized controlled trial.","volume":"121","author":"Zhang","year":"2024","journal-title":"Fertil Steril"},{"key":"R46-20260813","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.fertnstert.2006.12.064","article-title":"Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer.","volume":"91","author":"Papanikolaou","year":"2009","journal-title":"Fertil Steril"},{"key":"R47-20260813","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles.","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum Reprod"},{"key":"R48-20260813","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0015-0282(97)81407-0","article-title":"Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.","volume":"67","author":"Albano","year":"1997","journal-title":"Fertil Steril"},{"key":"R49-20260813","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10637-017-0466-8","article-title":"Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.","volume":"35","author":"Ito","year":"2017","journal-title":"Invest New Drugs"},{"key":"R50-20260813","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R51-20260813","first-page":"857","article-title":"Effect of basal serum luteinizing hormone and luteinizing hormone\/follicle-stimulating hormone ratio on outcomes of in vitro fertilization-embryo transfer in patients with polycystic ovarian syndrome (Chinese).","volume":"33","author":"Xujing","year":"2013","journal-title":"J South Med Univ"},{"key":"R52-20260813","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/REP-09-0187","article-title":"The impact of ovarian stimulation for IVF on the developing embryo.","volume":"139","author":"Santos","year":"2010","journal-title":"Reproduction"},{"key":"R53-20260813","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13048-024-01551-9","article-title":"Unraveling the complexity of follicular fluid: insights into its composition, function, and clinical implications.","volume":"17","author":"Pan","year":"2024","journal-title":"J Ovarian Res"},{"key":"R54-20260813","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/humrep\/dew183","article-title":"Correlation between aneuploidy, standard morphology evaluation and morphokinetic development in 1730 biopsied blastocysts: a consecutive case series study.","volume":"31","author":"Minasi","year":"2016","journal-title":"Hum Reprod"},{"key":"R55-20260813","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12958-020-00636-6","article-title":"Effect of endometrial thickness and embryo quality on live-birth rate of fresh IVF\/ICSI cycles: a retrospective cohort study.","volume":"18","author":"Lv","year":"2020","journal-title":"Reprod Biol Endocrinol"},{"key":"R56-20260813","first-page":"1433","article-title":"Mitochondrial proteome remodeling in oocytes from PCOS patients undergoing GnRH antagonist pretreatment.","volume":"41","author":"Chen","year":"2024","journal-title":"J Assist Reprod Genet"},{"key":"R57-20260813","doi-asserted-by":"crossref","first-page":"1492441","DOI":"10.3389\/frph.2025.1492441","article-title":"Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF\/ICSI antagonist protocols: a retrospective cohort study.","volume":"7","author":"Peng","year":"2025","journal-title":"Front Reprod Health"},{"key":"R58-20260813","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ijgo.12485","article-title":"The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol.","volume":"142","author":"Geng","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"R59-20260813","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/humrep\/dei386","article-title":"Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial.","volume":"21","author":"Lambalk","year":"2006","journal-title":"Hum Reprod"},{"key":"R60-20260813","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s11033-021-06976-9","article-title":"Basic aspects of endometrial receptivity in PCOS patients.","volume":"49","author":"Pathare","year":"2022","journal-title":"Mol Biol Rep"},{"key":"R61-20260813","first-page":"1026","article-title":"Comparison of GnRH agonist versus GnRH antagonist protocols in the COH of PCOS patients (Chinese).","volume":"11","author":"Xi","year":"2014","journal-title":"Guangxi Med Univ"},{"key":"R62-20260813","first-page":"2634","article-title":"Effects of three different stimulation protocols for ovulation induction on endometrial receptivity and pregnancy outcome in infertile patients with polycystic ovary syndrome (Chinese).","volume":"43","author":"Qiaoqiao","year":"2021","journal-title":"Zhejiang Med J"},{"key":"R63-20260813","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.fertnstert.2007.04.060","article-title":"GnRH antagonists may affect endometrial receptivity.","volume":"89","author":"Rackow","year":"2008","journal-title":"Fertil Steril"},{"key":"R64-20260813","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00404-020-05894-8","article-title":"Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis.","volume":"303","author":"Yang","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"R65-20260813","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00404-022-06565-6","article-title":"Ovarian stimulation protocols for poor ovarian responders: a network meta-analysis of randomized controlled trials.","volume":"307","author":"Di","year":"2023","journal-title":"Arch Gynecol Obstet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:05:57Z","timestamp":1786633557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":62,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042965","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}